Egypt’s pharma industry saw a collective 26.8% y-o-y growth in sales revenue in 1H2017 to EGP 23.1 bn, according to data from industry research firm Quintiles IMS picked up by Al Borsa. Novartis the industry chart with revenues of EGP 1.8 bn, followed by GlaxoSmithKline at EGP 1.4 bn. France’s Sanofi’s sales grew to EGP 1.2 bn in the first half of the year.
More from Enterprise
Central Bank of Egypt looks to renew USD 2 bn Kuwaiti deposit as regional conflict stalls FDI conversions
The maturing USD 2 bn deposit is expected to be…
Miga guarantee unlocks USD 313 mn for National Bank of Egypt trade finance
Plus: Incolease taps securitization market with debut EGP 2 bn…
Ceasefire optimism triggers EGX30 rally and EGP recovery
The EGP gained around 2.5% on the greenback by the…
IBF & Company doubles down on logistics with Techno Metal acquisition
Plus: Lucky lands USD 23 mn in Series B round,…